Previous Close | 1.0600 |
Open | 1.0800 |
Bid | 0.9200 x 900 |
Ask | 1.0700 x 800 |
Day's Range | 0.9100 - 1.0800 |
52 Week Range | 0.5500 - 16.1700 |
Volume | |
Avg. Volume | 104,243 |
Market Cap | 40.255M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0570 |
Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.46 |
Subscribe to Yahoo Finance Plus to view Fair Value for LABP
Raymond James downgraded Landos Biopharma Inc (NASDAQ: LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13 Phase 1b data in ulcerative colitis (UC). The analyst's rating change is driven by: Unclear strategy for omilancor in UC/Crohn's Disease (CD) (formulation optimization needed to improve solubility). Lack of conviction on NX-13's early efficacy data in UC until an adequately powered study is more clearly demonstrative of efficacy. The LAPB management t
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to Complete Comprehensive Review of Clinical Development Plans Later this Year NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical c
NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clini